Exor becomes a long-term investor in Philips supporting the company’s strategy


August 14, 2023

Joint announcement from Philips and Exor
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, and Exor N.V. (AEX: EXO), the Netherlands-based diversified holding company, announce they have entered into a relationship agreement as a result of which Exor has bought a 15% shareholding in Philips. This investment by Exor is fully supportive of Philips’ leadership, strategy and value creation potential and provides for Exor to nominate one member to the Supervisory Board of Philips.

Philips’ strategy and value creation plan with sustainable impact is based on its purpose to improve people's health and well-being through meaningful innovation. The company has leading market positions in attractive health technology market segments enabled by an innovative portfolio and strong customer base.

Exor aims to build great companies providing stable and committed support for their long-term value creation plans. The discussions between Exor and Philips were initiated in the context of Exor’s stated interest in increasing its presence in the healthcare and technology sectors. Exor’s investment in Philips will not result in any share dilution and has been carried out by way of on-market share purchases and an agreement with a major financial institution.

The relationship agreement includes Exor’s commitment to be a long-term minority investor and the right to propose one member to the Supervisory Board, as well as several customary conditions. While Exor does not plan to buy further Philips shares in the short term, over time the relationship agreement provides for Exor, at its discretion, to increase its participation to a maximum limit of 20% of Philips’ outstanding ordinary share capital. The relationship agreement can be accessed here.

Roy Jakobs, CEO of Royal Philips, said: “Exor’s investment in Philips, their long-term outlook and increased focus on healthcare and technology, fit well with our strategy and substantial value creation potential. With our market leadership positions and people-centric innovation capabilities, Philips is well positioned to deliver on our purpose to improve the health and well-being of people, creating value for all stakeholders.”

Feike Sijbesma, Chairman of the Supervisory Board of Royal Philips, said: “We welcome Exor as a long-term investor in Philips. They have a successful track record and clear strategy to grow and develop in healthcare and technology. Exor’s substantial investment underlines their confidence in Philips’ transformation into a healthcare technology company and its growth and value potential.”

John Elkann, Exor’s CEO, commented: “The path of change taken by Philips in recent years has created a company that combines two areas – healthcare and technology – to which we are committed. Our discussions have confirmed the strong and positive alignment between our long-term, supportive approach to our companies and Philips’ ambitious plans under the chairmanship of Feike Sijbesma and the executive team led by Roy Jakobs.”

For further information, please contact:

Philips Global Media Relations
Steve Klink
Tel.: +31 6 10888824
E-mail: steve.klink@philips.com

Philips Investor Relations
Leandro Mazzoni
Tel.: +31 20 5977055
E-mail: leandro.mazzoni@philips.com

Exor Media Relations
Tel.: + 31 20 240 2221
E-mail: media@exor.com

Exor Investor Relations
Tel.: + 31 20 240 2222
E-mail: ir@exor.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 71,500 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About Exor
Exor N.V. (AEX: EXO), is the Netherlands based diversified holding company, listed on the AEX. For over a century, Exor has built great companies and made successful investments worldwide with a culture that combines entrepreneurial spirit and financial discipline. With a Net Asset Value of around EUR 33 billion, its portfolio is principally made up of companies in which Exor is the largest shareholder including Ferrari, Stellantis and CNH Industrial. More recently, in the healthcare sector Exor has made important investments in Institut Mérieux and in Lifenet Healthcare while in the technology sector it has become the largest single shareholder in VIA Transportation Inc.

Forward-looking statements
This statement contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.

This press release contains inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

Attachments

  • A Philips Azurion Image-Guided Therapy system in use
  • Philips CT scanner operated by doctor and tech support in the control room
  • A nurse reassuring a child and mother before the MRI exam by means of Pediatric Coaching
  • A nurse using EPIQ Elite Ultrasound system
  • Mother and kid brushing with the new Sonicare for Kids Pets


Exor becomes a long-term investor in Philips supporting the company’s strategy

THỦ THUẬT HAY

5 thủ thuật Registry tăng tốc máy tính Windows 8 nhanh hơn

Không thể phủ nhận tốc độ khởi động của Windows 8 và Windows 8.1 nhanh hơn hẳn các phiên bản Windows trước, Windows 7 và Windows Vista. Tuy nhiên cũng giống như các phiên bản trước, sau khi sử dụng một thời gian, máy

Cách đăng nhập VNEID bằng vân tay đăng nhập không cần nhớ mật khẩu

Không phải lúc nào ta cũng nhớ mật khẩu và việc nhập mật khẩu cũng khá tốn thời gian. Vì vậy đây là cách đăng nhập VNEID bằng vân tay cho bạn.

Xử lý nhanh màn hình iPhone không lên/ bị đen

TCN sẽ hưỡng dẫn độc giải cách giải quyết tạm thời màn hình iPhone/iPad bị đen trong khi các chức năng vẫn hoạt động bình thường.

Dùng thử ứng dụng Skype mới được thiết kế lại trên Mac và Windows

Hẳn người dùng không còn lạ lẫm gì với Skype - ứng dụng chat và gọi video trên điện thoại cũng như máy tính. Mới đây, Microsoft đã quyết định 'khoác áo mới' cho ứng dụng này. Phiên bản preview của bản cập nhật này đã

Bạn có biết về sự khác nhau giữa màu sắc tin nhắn trên iPhone không?

Nếu bạn đang sở hữu một chiếc iPhone, chắc hẵn bạn đã nhận ra một điều kì lạ ở các tin nhắn: một số có màu xanh lá, trong khi số khác lại là xanh dương. Vậy nguyên nhân cho sự việc này là gì?

ĐÁNH GIÁ NHANH

Đánh giá BMW X4 2019 về thiết kế vận hành và giá bán

BMW X4 2019 đã xuất hiện tại các đại lý ở Mỹ, cạnh tranh trực tiếp với Mercedes-Benz GLC coupe. Các phiên bản xDrive30i tiêu chuẩn có giá khởi điểm là 51.445 USD (tương đương 1,2 tỷ đồng) và M40i có giá 61.445 USD

Đánh giá chi tiết Galaxy J6: Có đáng lựa chọn trong tầm giá 5 triệu không?

Nhỏ và Dài là 2 cảm nhận đầu tiên của mình khi cầm vào Galaxy J6, dù là một thiết bị có màn hình đến 5,7 inch, nhưng cảm giác cầm chiếc J6 trên tay chỉ bằng cầm một chiếc iPhone “phiên bản không plus” với màn hình 4.7

Trên tay Vivo Y33s – Smartphone hơn 5 triệu, camera 50MP

Vivo Y33s là bản kế nhiệm của Vivo Y31 2021 được nâng cấp và cải tiến rất nhiều. Camera, vi xử lý, tuổi thọ pin và đặc biệt giá bán chỉ dưới 6 triệu đồng. Bài viết trên tay vivo Y33s dưới đây sẽ giúp bạn hiểu rõ hơn về